



EXHIBIT A

PENDING CLAIMS

(As of Entry of Amendment Filed June 26, 2001)

**U.S. APPLICATION SERIAL NO. 09/070,629
(ATTORNEY DOCKET NO. 6923-071)**

1. A recombinant influenza virus the genome of which contains a region encoding a tumor-associated antigen.
2. The recombinant influenza virus of Claim 1, 20, 21, 22, 23, 24 or 25 in which the region is contained within a structural gene of influenza virus.
3. The recombinant influenza virus of Claim 2 in which the structural gene is HA, NA, NP or M.
4. The recombinant influenza virus of Claim 1, 20, 21, 22, 23, 24 or 25 in which the region encoding the tumor-associated antigen is in a bicistronic arrangement with an influenza virus gene.
5. The recombinant influenza virus of claim 1, 20, 21, 22, 23, 24 or 25 which is attenuated.
20. The recombinant influenza virus of Claim 1 wherein the tumor-associated antigen is a human tumor antigen recognized by T lymphocytes.
21. The recombinant influenza virus of Claim 20 wherein the human tumor antigen is a melanocyte tumor antigen.
22. The recombinant influenza virus of Claim 20 wherein the human tumor antigen is a breast, ovarian, cervical or pancreatic carcinoma antigen.

23. The recombinant influenza virus of Claim 20 wherein the human tumor antigen is MAGE-1, MAGE-3, BAGE, GAGE-1, GAGE-2, N-acetylglucosaminyltransferase, or p15.

24. The recombinant influenza virus of Claim 20 wherein the human tumor antigen is beta-catenin, MUM-1, or CDK4.

25. The recombinant influenza virus of Claim 20 wherein the human tumor antigen is HER-2/neu, human papillomavirus-E6, human papillomavirus-E7, or MUC-1.

26. An immunogenic formulation comprising an effective amount of the recombinant influenza virus of Claim 4 and a pharmaceutically acceptable carrier.

27. An immunogenic formulation comprising an effective amount of the recombinant influenza virus of Claim 5 and a pharmaceutically acceptable carrier.

28. A vaccine formulation comprising an effective amount of the recombinant influenza virus of Claim 4 and a pharmaceutically acceptable carrier.

29. A vaccine formulation comprising an effective amount of the recombinant influenza virus of Claim 5 and a pharmaceutically acceptable carrier.